| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
ANT-3310 sodium targets serine β-lactamases (SBLs), enzymes that hydrolyze β-lactam antibiotics and confer resistance in bacteria. It is a covalent inhibitor that uses a strained urea moiety as the warhead to react with the active serine residue in the active site of SBLs. By irreversibly inhibiting these enzymes, ANT-3310 sodium restores the activity of β-lactam antibiotics against resistant bacteria. It potentiates the activity of β-lactam antibiotics against Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB).
|
|---|---|
| ln Vitro |
ANT-3310 sodium (Compound 21, 0.006 to 3 000 nM, 10 min) inhibits a series of Serine β-Lactamase (AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2), with IC<>50 values ranging from 1 nM to 175 nM[1]. ANT3310 sodium shows a low in vitro cytotoxicity (IC<>50: > 100 μM) in HepG2 cell, cardiotoxicity (inhibition of the hERG potassium ion channel), and genotoxicity (Ames test)[1]. |
| ln Vivo |
ANT-3310 sodium (intravenous injection, 25-100 mg/kg, at 1, 3, 5, and 7 h postinfection) reduces bacterial burdens in murine thigh infection model[1]. ANT3310 sodium (intravenous injection, 1 mg/kg, Male Swiss albino mice) shows a T1/2 value of 0.64 h, AUC value of 412 ng•h/mL, and Cl value of 40 mL/min/kg (pharmacokinetic assay)[1]. Animal Model: Murine thigh infection model[1] Dosage: 25, 50, and 100 mg/kg Administration: Intravenous injection, at 1, 3, 5, and 7 h postinfection Result: Reduced bacterial burdens (colony forming units, CFU) in a dose-dependent manner to levels below that of the initial starting inoculum at the highest dose, when treated with the combination of MEM. |
| Enzyme Assay |
In vitro enzyme assays for ANT-3310 sodium measure its inhibition of serine β-lactamases. Purified enzymes (AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, KPC-2) are incubated with varying concentrations of the compound for 10 minutes. Enzyme activity is measured using chromogenic or fluorogenic substrates. IC50 values ranging from 1 nM to 175 nM are determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for ANT-3310 sodium are conducted in HepG2 cells to assess cytotoxicity (IC50 > 100 μM). Cardiotoxicity is assessed by inhibition of the hERG potassium ion channel. Genotoxicity is assessed using the Ames test. Antibacterial activity is assessed in bacterial cultures by determining the minimum inhibitory concentration (MIC).
|
| Animal Protocol |
Animal Model: Murine thigh infection model[1]
Dosage: 25, 50, and 100 mg/kg Administration: Intravenous injection, at 1, 3, 5, and 7 h postinfection Result: decreased, when treated with the combination of MEM, bacterial burdens (colony forming units, or CFU) in a dose-dependent manner to levels below that of the initial starting inoculum at the highest dose. In vivo animal experiments with ANT-3310 sodium are conducted in a murine thigh infection model. The compound is administered intravenously at doses of 25, 50, and 100 mg/kg at 1, 3, 5, and 7 hours post-infection. Bacterial burdens (colony forming units, CFU) are measured in thigh tissues. These studies demonstrate the compound's in vivo efficacy against bacterial infections. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ANT-3310 sodium include a T1/2 value of 0.64 h, an AUC value of 412 ng·h/mL, and a Cl value of 40 mL/min/kg (in male Swiss albino mice at 1 mg/kg, intravenous). The compound has a molecular formula of C6H8FN2NaO5S and a molecular weight of 262.19. Storage: powder at -20°C for 3 years; in solvent at -80°C for 6 months.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for ANT-3310 sodium indicate low in vitro cytotoxicity (IC50 > 100 μM in HepG2 cells), low cardiotoxicity (hERG inhibition), and low genotoxicity (Ames test). The compound is for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
ANT-3310 sodium has CAS number 2410688-61-6, molecular formula C6H8FN2NaO5S, and molecular weight 262.19. Synonyms: ANT3310. It is a novel covalent serine β-lactamase inhibitor of the diazabicyclooctane class. It inhibits serine β-lactamase with IC50 values from 1 nM to 175 nM. Purity: ≥98%. Not for human use; for research purposes only.
|
| Molecular Formula |
C6H8FN2NAO5S
|
|---|---|
| Molecular Weight |
262.191294670105
|
| Exact Mass |
240.02
|
| Elemental Analysis |
C, 27.49; H, 3.08; F, 7.25; N, 10.68; Na, 8.77; O, 30.51; S, 12.23
|
| CAS # |
2410688-61-6
|
| Related CAS # |
2410688-60-5 (free acid);2410688-61-6 (sodium);
|
| PubChem CID |
153516440
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
385
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)[O-])F.[Na+]
|
| InChi Key |
UIJIKXQAJBMNIR-JBUOLDKXSA-M
|
| InChi Code |
InChI=1S/C6H9FN2O5S.Na/c7-5-2-1-4-3-8(5)6(10)9(4)14-15(11,12)13/h4-5H,1-3H2,(H,11,12,13)/q+1/p-1/t4-,5+/m1./s1
|
| Chemical Name |
sodium (2R,5R)-2-fluoro-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate
|
| Synonyms |
ANT3310; ANT 3310; ANT-3310; ANT3310 sodium;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~953.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8140 mL | 19.0701 mL | 38.1403 mL | |
| 5 mM | 0.7628 mL | 3.8140 mL | 7.6281 mL | |
| 10 mM | 0.3814 mL | 1.9070 mL | 3.8140 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
